Drug intelligence / Profile preview

bromhexine + guaifenesin + terbutaline

Development stage
Unknown
Lead developer
Caplet India
Modality
Small Molecules
Administration
Oral
01

Overview

VENTEX is a fixed-dose combination medication developed by Caplet India, primarily indicated for the treatment of productive cough associated with bronchospasm in respiratory conditions such as bronchial asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, and emphysema. The combination consists of three active pharmaceutical ingredients: terbutaline, bromhexine, and guaifenesin. Terbutaline is a selective beta-2 adrenergic receptor agonist that acts as a bronchodilator, relaxing airway smooth muscle to ease breathing. Bromhexine is a mucolytic agent that thins and loosens thick phlegm by disrupting mucopolysaccharide fibers. Guaifenesin is an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions, facilitating their clearance via the cough reflex. Together, these components work synergistically to relieve chest congestion and improve airway clearance.

Brand names
VentexVentex Forte
Other names
bromhexine + guaifenesin + terbutalinebromhexine hydrochloride + guaifenesin + terbutaline sulfatebromhexine, guaifenesin and terbutalineguaifenesin + bromhexine + terbutalineguaifenesin, bromhexine and terbutalineterbutaline + bromhexine + guaifenesinterbutaline, bromhexine and guaifenesin
02

Targets

ADRB1 (β1)ADRB2 (β2)

Beyond the preview

Go deeper on bromhexine + guaifenesin + terbutaline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bromhexine + guaifenesin + terbutaline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call